ABCL - Company ID 0001703057
The table below shows AbCellera Biologics Inc.'s balance sheet line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & equivalents | $128.51M | $156.32M | $133.32M | $386.54M | $476.14M |
| Short-term investments | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Inventory | $6.34M | - | - | - | - |
| Total current assets | $728.23M | $751.37M | $871.99M | $1.03B | $929.80M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Property, plant & equipment | - | - | - | $217.25M | $111.62M |
| Goodwill | $47.81M | $47.81M | $47.81M | $47.81M | $47.81M |
| Total assets | $1.36B | $1.36B | $1.49B | $1.54B | $1.32B |
| Accounts payable | - | - | - | - | - |
| Total current liabilities | $64.31M | $76.61M | $119.01M | $118.32M | $120.68M |
| Long-term debt | - | - | - | - | - |
| Total liabilities | $390.05M | $304.47M | $335.78M | $307.63M | $292.84M |
| Retained earnings | -$29.48M | $116.93M | $279.79M | $426.19M | $267.67M |
| Total equity | $966.90M | $1.06B | $1.15B | $1.23B | $1.03B |